Prosecution Insights
Last updated: May 29, 2026
Application No. 17/610,334

INSTRINSICALLY LUBRICATING DRUG-LOADED HYDROGELS FOR USE AS PROPHYLACTIC MEDICAL DEVICES

Non-Final OA §103
Filed
Nov 10, 2021
Priority
May 14, 2019 — provisional 62/847,476 +1 more
Examiner
RONEY, CELESTE A
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Trustees of the University of Pennsylvania
OA Round
3 (Non-Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
457 granted / 733 resolved
+2.3% vs TC avg
Strong +18% interview lift
Without
With
+18.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
51 currently pending
Career history
798
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
69.9%
+29.9% vs TC avg
§102
1.3%
-38.7% vs TC avg
§112
2.0%
-38.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 733 resolved cases

Office Action

§103
DETAILED ACTION Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/16/2025 has been entered. Previous Rejections Applicant’s arguments, filed 10/16/2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Response to Arguments Applicant’s arguments with respect to claim 12 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Claim Rejections - 35 USC § 103 - Obviousness The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 12-18 and 20 are rejected under 35 U.S.C. 103 as being unpatentable over Havenstrite et al (US 2017/0360994), in view of Elton et al (USP 5,290,585 A), further in view of Beck et al (US 2009/0280182 A1) and further in view of Aizenberg et al (US 2008/0095977 A1). Havenstrite taught medical devices (e.g., endoscope, at ¶ [0010] and at claim 9; drug depot at ¶ 0116 and at claim 2), coated thereon, by covalent attachment, with a hydrogel layer. The hydrogel layer included a first species comprising polyethylene glycol (PEG) and a second species comprising polyacrylamide (PAM) [abstract]. Substrates were disclosed [0107, 0183, 0209, 0211, 0297-0298]. An outer hydrogel network comprised of interpenetrating polymer networks formed in either simultaneous or sequential polymerization steps. For example, upon forming the initial outer hydrogel layer, the layer can be swollen in a monomer solution along with a crosslinker and initiator. Upon exposure to UV light, a second interpenetrating network will form. The double network confers additional mechanical strength and durability, while maintaining high water content and high biocompatibility [0112]. Havenstrite differs from the claimed invention in that Havenstrite was not specific that the hydrogel materials were self-lubricating; that the double interpenetrating network comprising a first and second network had interconnections between the two networks; that the hydrogel materials covalently bound a layer of methacrylate bound to a substrate, as recited in claim 12. Elton taught lubricious hydrogel coatings on medical devices introduced into the body [abstract and title]. The coatings were hydrophilic, extremely lubricious and retained lubricity (e.g., reads on self-lubricating), wherein the coatings exhibited a significantly reduced coefficient of friction [abstract; col 2, lines 27-31]. As per Elton, it has long been known that hydrophilic coatings with low friction (coefficient of friction of 0.3 or less) are useful for a variety of medical devices. When low friction surfaces are used, the devices, upon introduction into the body, slide easily with arteries, veins, cannula and other body orifices and passageways [col 1, lines 9-15]. Beck taught interpenetrating network hydrogels incorporated into implants and devices [abstract]. Devices comprised a first cross-linked (e.g., a covalently cross-linked) polymer network and a second polymer network that was cross-linked and/or polymerized in the presence of the first polymer network. The first polymer network was PEG. The second polymer network was a hydrophilic and/or ionizable polymer network, e.g., a cross-linked polyacrylamide (PAAm) network [0064-0065]. FIG. 1 of Beck illustrates an example of an interpenetrating hydrogel comprising a first cross-linked polymer network fully interpenetrated by a second cross-linked polymer network [0030]. The two polymer networks are irreversibly entwined with each other by the formation of covalent bonds. In certain variations of hydrogels, two polymer networks may interact in addition to being entangled, e.g., hydrogen bonding may be present between groups on two different polymer networks (e.g., reads on interconnections between the two networks), wherein bonding increased the mechanical strength and physical properties of the hydrogel [0066, 0068]. Aizenberg taught an apparatus, as a drug-release system, comprising an anchoring layer, which acted as an adhesive layer configured to attach a substrate. In one embodiment, an anchoring layer of poly (glycidylmethacrylate) (PGMA) was covalently bonded to both the substrate and a polyacrylamide hydrogel layer [¶s 0038 and 0054; claim 18]. Since Havenstrite taught hydrogel-coated medical devices for entry into the body (e.g., endoscope), it would have been prima facie obvious to one of ordinary skill in the art to include, within the teachings of Havenstrite, self-lubricating hydrogel materials, as taught by Elton. The ordinarily skilled artisan would have been motivated to easily slide the medical device within the arteries, veins, cannula and other body orifices and passageways, as taught by Elton [Elton, at col 1, lines 9-15; col 2, lines 27-31; and, at the abstract]. Since Havenstrite taught hydrogel coated medical devices comprising a double interpenetrating network, it would have been prima facie obvious to one of ordinary skill in the art to include, within the teachings of Havenstrite, interconnections between the first and second networks, as taught by Beck. The ordinarily skilled artisan would have been motivated to increase the mechanical strength and physical properties of the hydrogel, as taught by Beck [Fig. 1, abstract, 0030, 0064-0066, 0068]. Since Havenstrite taught drug depots, it would have been prima facie obvious to one of ordinary skill in the art to include, within the teachings of Havenstrite, an anchoring layer of poly (glycidylmethacrylate) (PGMA), covalently bonded to both the substrate and a polyacrylamide hydrogel layer, as taught by Aizenberg. The ordinarily skilled artisan would have been motivated to provide a drug-release system, as taught by Aizenberg [¶s 0038 and 0054; claim 18]. Havenstrite, in view of Elton, Beck and Aizenberg, reads on claims 12-13, 18 and 20. Claims 14-15 are rendered prima facie obvious because Havenstrite taught that the coatings can be formed on a surface of a medical device, or in an aqueous solution (e.g., before being applied upon the device; e.g., reads on free-standing without a base material) [0032, 0188]. Claims 16-17 are rendered prima facie obvious because Havenstrite taught active agents, including antimicrobial agents (e.g., reads on antifouling product) [0110-0111]. The instant claim 20 recites a friction coefficient of 1 or lower. Elton taught a coefficient of 0.02 at Examples 12 and 14. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art", a prima facie case of obviousness exists. MPEP 2144.05 A. Claim(s) 19 is are rejected under 35 U.S.C. 103 as being unpatentable over Havenstrite et al (US 2017/0360994), in view of Elton et al (USP 5,290,585 A) further in view of Beck et al (US 2009/0280182 A1), further in view of Aizenberg et al (US 2008/0095977 A1).and further in view of Choudhury et al (US 2019/0060530 A1). The 35 U.S.C. 103 rejection over Havenstrite, in view of Elton, Beck and Aizenberg, was previously discussed. Additionally, Havenstrite taught the hydrogel comprising a hydrophilic layer [claim 1] comprising a first and second species, each of the 1st or 2nd species comprising PAM and/or alginate [claims 82-83], whereby the 1st and 2nd species formed cross-links to react [claim 87], and covalently bond to the outer surface of the device [claim 89]. Furthermore, Havenstrite taught the water content of the hydrogel layer at between about 80 % to 98 % [claim 33]. Although Havenstrite taught hydrogels comprising crosslinked PAM and alginate, Havenstrite was not specific the amount of the combined acrylamide and alginate, as recited in claim 19. Choudhury taught hydrogels [claim 1] comprising crosslinked polyacrylamide and alginate [claim 8], wherein the ratio of the water/polymer was 86% to 14 %, adjustable to a ratio of 75 % to 25 % [claim 2; ¶ 0035]. The ratio provided a highly stretchy, elastic and bendable tough gel, able to withstand a high level of torsion deformation [0012-0014]. Since Havenstrite taught hydrogels comprising crosslinked PAM and alginate, it would have been prima facie obvious to one of ordinary skill in the art to include, within the teachings of Havenstrite, amounts thereof (PAM and alginate), as taught by Choudhury. The ordinarily skilled artisan would have been motivated to provide a highly stretchy, elastic and bendable tough gel, able to withstand a high level of torsion deformation, as taught by Choudhury [Choudhury at ¶s 0012-0014 and 0035; and, at claims 1 and 8]. It would have been prima facie obvious to the ordinarily skilled artisan to include within Havenstrite, the polymers at a water/polymer ratio of 86% to 14 %, adjustable as desired, because at this ratio, the hydrogel is highly stretchy, elastic, bendable, and is able to withstand a high level of torsion deformation, as taught by Choudhury. The instant claim 19 recites 75-90 % water and 10-25 % combined acrylamide and alginate. Havenstrite taught 80-98 % water. Choudhury taught a water/polymer ratio of 86% to 14 %, adjustable as desired. A prima facie case of obviousness exists because of overlap, as discussed above. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CELESTE A RONEY whose telephone number is (571)272-5192. The examiner can normally be reached Monday-Friday; 8 AM-6 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kaup S Sahana can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CELESTE A RONEY/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Nov 10, 2021
Application Filed
Feb 15, 2023
Response after Non-Final Action
Sep 27, 2024
Non-Final Rejection mailed — §103
Feb 20, 2025
Response Filed
Jun 16, 2025
Final Rejection mailed — §103
Oct 16, 2025
Request for Continued Examination
Oct 20, 2025
Response after Non-Final Action
Dec 23, 2025
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12616712
STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERS
3y 3m to grant Granted May 05, 2026
Patent 12611471
A COMPOSITE FERRITE NANOPARTICLE WITH SYNERGISTIC ENHANCEMENT OF LIVER SPECIFICITY AND PREPARATION METHOD AND APPLICATION THEREOF
3y 3m to grant Granted Apr 28, 2026
Patent 12605486
AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF
5y 7m to grant Granted Apr 21, 2026
Patent 12605455
CAR Peptide for Improved Coronavirus Survival
3y 7m to grant Granted Apr 21, 2026
Patent 12599573
COMPOSITIONS AND USES THEREOF IN TREATING CANCERS
3y 0m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
80%
With Interview (+18.0%)
3y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 733 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month